ArticleJournal of medical virology2026
Hepatitis B Core-Related Antigen Level Predicts Disease Progression in the Gray Zone Hepatitis B Patients.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe natural history of hepatitis B virus (HBV) infection does not always conform to the currently defined phases, and some patients who do not clearly meet established treatment criteria are classified as in the gray zone (GZ). We investigated the factors for progression of hepatitis B e antigen (HBeAg)-negative GZ patients to chronic hepatitis (CH): HBV DNA levels ≥ 3.3 log IU/mL and alanine aminotransferase (ALT) ≥ 31 U/L.
methodsThis study included 102 HBeAg-negative GZ patients (81 with high HBV DNA levels and normal ALT levels, and 21 with low HBV DNA levels and high ALT levels), and who underwent liver stiff measurement using transient elastography.
resultsOf 91 patients followed up for more than 6 months, 19 progressed to CH, and the cumulative incidence rate of progression to CH at 5 years was 17.5%. Multivariate analysis showed that only the hepatitis B core-related antigen (HBcrAg) level was independently associated with progression to CH (HR 3.08; p = 0.003). Receiver operating characteristic curve analysis to assess the effectiveness of HBcrAg levels in predicting progression to CH showed the area under the curve was 0.828, and the optimal cut-off value was determined to be 2.87 log U/mL. When applying this cut-off, the cumulative incidence rates of progression to CH were significantly divided (p < 0.001): 5-year rates were 39.1% in patients with HBcrAg levels ≥ 2.87 log U/mL and 2.9% in those with levels < 2.87 log U/mL.
conclusionsHBcrAg levels are useful for predicting progression to CH by HBeAg-negative GZ patients. CLINICAL
trial registrationThe study protocol was approved by the Institutional Review Board of Nagoya City University (approval number: 60-00-0657).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.